skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

$name

無料の最新記事&レポート

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Celltrion Makes Progress On Coronavirus Treatment

    Coronavirus_Elbow_pump

    Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.

    Topic Coronavirus

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Trialtrove: 医療用医薬品の臨床試験情報デ...

    COVID-19 Infographic

    COVID-19 Infographic

    Access the infographic below which explores the number of treatment drugs for COVID-19 currently in clinical trials or in development, events including progress updates, partnerships, regulatory and trial announcements etc, and the number of articles published on COVID-19 as of March 3, 2020. This data has been tracked and reported via Informa Pharma Intelligence’s clinical, regulatory and commercial data and analytics, and news and insight tools including Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet, Medtech Insight, and Generics Bulletin etc.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Sandoz, Teva And Mylan Step Up On Hydroxychloroquine

    To meet expected demand in the weeks and months ahead, Novartis' Sandoz has committed to donate up to 130 million doses of generic hydroxychloroquine – a treatment for malaria currently under investigation as a therapy to aid in the COVID-19 pandemic – while Teva and Mylan have also made strides, as the generics industry continues to play its part in tackling the coronavirus outbreak.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Preserving Full Capacity Is Key To Global Coronavirus Reponse

    Leaders around the world must do all they can to ensure that medicines manufacturing and the supply chain are operating at full capacity as part of efforts to tackle the coronavirus outbreak, global off-patent industry association the IGBA has urged.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Celltrion Pledges Efforts on Coronavirus Antibody And Kit

    Celltrion unveils emergency plans to deal with the COVID-19 situation in South Korea by speeding up development of a potential therapeutic antibody and rapid, accurate testing kit without considering economic returns.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Green Lanes Will Help EU Fight Coronavirus

    Industry has welcomed the European Commission’s introduction of priority freight lanes, or ‘green lanes’, for essential goods to help address the challenges posed by the coronavirus outbreak.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    European Coronavirus Planning Requires ‘Structured Dialog’

    European off-patent industry association Medicines for Europe has called on the European Commission to urgently establish a “structured dialog” involving industry stakeholders, to help plan for an extended outbreak of coronavirus.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Sun Finds US ‘Challenging’

    Sun Pharma’s Indian domestic operations posted strong sales in the third quarter, but this was not enough to prevent the company from reporting a 26% tumble in consolidated net profit in the face of a “challenging” US generics market and slow approvals for complex products.

    Topic deal-trends

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Who’s Hired? Sandoz Germany Seeks A New Country Head

    While Sandoz looks for a new country head in Germany, Lupin has appointed a new chief corporate development officer and a Coherus executive has left the firm.

    Topic business-strategies

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Celltrion Sets Out Strategy For China

    Celltrion has unveiled plans to construct a biologics plant in Wuhan, China, as well as setting up a direct sales network in the country, as part of its wider global strategy that also involves launching a new biosimilar every year to 2030.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Coherus Is Confident After US Ranibizumab Filing

    Coherus_Is_Confident_After_US

    Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.

    Topic Biosimilars Deal trends

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    California Plans To Create Own Generics Label

    California’s 2020-2021 fiscal budget includes plans to work with manufacturers to establish the state’s own generics label. But industry is sceptical that the initiative will deliver the savings that the US state hopes for.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Biocon Biologics Gets True North Investment

    Biocon_Biologics_Gets_True_North_Investment

    Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.

    Topic deal-trends strategy

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Alberta Is Second Canadian Province To Switch To Biosimilars

    Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Global Industry Hails Bioequivalence Progress

    For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。